SD
Sumitomo Dainippon Pharma
Japan - Oita
PharmaceuticalFocus: Small Molecules
Sumitomo Dainippon Pharma is a life sciences company focused on Small Molecules.
EndocrinologyNephrologyNeurology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (4)
2 discontinued products not shown
APTIOM
eslicarbazepine acetate
Peak
ORAL · TABLET
eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
partial-onset seizures in patients 4 years of ageolder
2013
0
GEMTESA
vibegron
Peak
ORAL · TABLET
Adrenergic beta3-Agonists
2020
0
MYFEMBREE
relugolix, estradiol hemihydrate, and norethindrone acetate
Peak
ORAL · TABLET
Gonadotropin Releasing Hormone Receptor Antagonists
2021
0
ORGOVYX
relugolix
Peak
ORAL · TABLET
Gonadotropin Releasing Hormone Receptor Antagonists
2020
0
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 6 approved products
Top TAs: Endocrinology, Nephrology, Neurology
Portfolio Health
Peak6 (100%)
6 total products
Therapeutic Area Focus
Marketed
Pipeline